168 related articles for article (PubMed ID: 10734294)
1. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Toze CL; Shepherd JD; Connors JM; Voss NJ; Gascoyne RD; Hogge DE; Klingemann HG; Nantel SH; Nevill TJ; Phillips GL; Reece DE; Sutherland HJ; Barnett MJ
Bone Marrow Transplant; 2000 Mar; 25(6):605-12. PubMed ID: 10734294
[TBL] [Abstract][Full Text] [Related]
2. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
4. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
5. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
Pavletic SZ; Khouri IF; Haagenson M; King RJ; Bierman PJ; Bishop MR; Carston M; Giralt S; Molina A; Copelan EA; Ringdén O; Roy V; Ballen K; Adkins DR; McCarthy P; Weisdorf D; Montserrat E; Anasetti C
J Clin Oncol; 2005 Aug; 23(24):5788-94. PubMed ID: 16043827
[TBL] [Abstract][Full Text] [Related]
8. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
Toze CL; Galal A; Barnett MJ; Shepherd JD; Conneally EA; Hogge DE; Nantel SH; Nevill TJ; Sutherland HJ; Connors JM; Voss NJ; Kiss TL; Messner HA; Lavoie JC; Forrest DL; Song KW; Smith CA; Lipton J
Bone Marrow Transplant; 2005 Nov; 36(9):825-30. PubMed ID: 16151430
[TBL] [Abstract][Full Text] [Related]
9. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic transplantation in malignant lymphoma].
Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
12. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia.
Doney KC; Chauncey T; Appelbaum FR;
Bone Marrow Transplant; 2002 May; 29(10):817-23. PubMed ID: 12058231
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma.
Forrest DL; Thompson K; Nevill TJ; Couban S; Fernandez LA
Bone Marrow Transplant; 2002 Jun; 29(12):973-8. PubMed ID: 12098065
[TBL] [Abstract][Full Text] [Related]
16. Allografting for indolent lymphoid neoplasms.
Toze CL; Shepherd JD; Connors JM; Voss NJ; Gascoyne RD; Hogge DE; Klingemann HG; Nantel SH; Nevill TJ; Phillips GL; Reece DE; Sutherland HJ; Conneally EA; Barnett MJ
Ann Oncol; 2000; 11 Suppl 1():59-61. PubMed ID: 10707781
[TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation.
Toze CL; Barnett MJ; Connors JM; Gascoyne RD; Voss NJ; Nantel SH; Nevill TJ; Shepherd JD; Sutherland HJ; Lavoie JC; Forrest DL; Song KW; Hogge DE
Br J Haematol; 2004 Nov; 127(3):311-21. PubMed ID: 15491292
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]